Pediatric Moratorium! Adult Use Restrictions! Veterinary Prohibition!
"Codon Optimization in mRNA Vaccines and Gene Therapies: An Assessment of Protein Misfolding Risks and Regulatory Oversight" submitted to the FDA's Vaccines and Related Biological Products Advisory Committee!
Here's the Executive Summary

Objective: This white paper evaluates the scientific evidence and regulatory oversight related to codon optimization in messenger RNA (mRNA) vaccines and gene therapies for both human and animal applications. Its primary goal is to assess whether the potential risks—specifically protein misfolding, aggregation, and associated diseases like amyloidogenesis and prionogenesis—justify a moratorium on this technology’s use. The analysis aims to inform policy by balancing innovation with safety.

Scope: The assessment covers the principles of codon optimization, the mechanisms of protein folding and misfolding during translation, and the risks of amyloid formation and prion-like propagation. It reviews regulatory frameworks, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Chemistry, Manufacturing, and Controls (CMC) requirements. The scope includes a detailed examination of scientific literature—both foundational and recent—such as studies on tissue-specific codon usage, codon context effects, and structural risks in mRNA vaccines. It also analyzes preclinical and clinical safety data, pharmacovigilance reports, and a case study on COVID-19 mRNA vaccines. Additionally, the paper explores implications for veterinary vaccines and food chain safety, concluding with an updated risk management and policy evaluation.

Key Findings: Codon optimization enhances protein production in mRNA-based vaccines and therapies but introduces risks that challenge its presumed safety. New research shows that changing codons—previously thought to be neutral—affects translation speed and accuracy, potentially leading to protein misfolding and aggregation. For example, the cardiomyocyte PAO model reveals that misfolded proteins can cause delayed, severe damage, such as heart failure, broadening concerns beyond brain-related diseases. Data from TissueCoCoPUTs indicate that generic codon optimization often mismatches the translation needs of specific tissues, increasing misfolding risks. In COVID-19 mRNA vaccines, structural issues like excessive G-quadruplex formation may heighten these dangers.
Regulatory oversight, however, falls short. There are no standard tests to evaluate how codon changes affect protein shape or clumping, and long-term monitoring is insufficient to detect slow-developing issues like neurodegeneration or prion-like diseases. The rapid rollout of COVID-19 mRNA vaccines lacked thorough evaluation of these folding risks. In veterinary applications, the use of codon-optimized therapies in livestock raises unresolved concerns about misfolded proteins entering the food chain and environment, potentially affecting human health.

Conclusion on Moratorium
Given the mounting evidence of risk and gaps in oversight, a tiered moratorium is recommended as the most cautious and effective approach:

· Pediatric Moratorium: Codon-optimized mRNA vaccines and gene therapies should not be used in children under 18 until safer practices are developed. This includes using tissue-specific codon designs, conducting 24-month safety studies in primates, and setting limits on G-quadruplex formation. Children’s developing tissues are especially vulnerable, and long-term data are lacking.

· Adult Use Restrictions: New clinical trials for risky mRNA designs—those with heavy optimization, high clumping potential, or rich GC content—should pause. This halt would last until advanced tests, such as Kinetic Folding Assurance (KFA), hidden gene screening, and cross-seeding checks, are required.

· Veterinary Prohibition: Codon-optimized gene therapies in animals entering the food supply should be banned. Evidence from the PAO model and prion diseases suggests a risk of transmissible misfolded proteins, posing a threat